A Kagramanova
A5008601428- Inflammatory Bowel Disease
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders
- Pharmacological Effects of Natural Compounds
- Eosinophilic Esophagitis
- Biomarkers in Disease Mechanisms
- Diagnosis and treatment of tuberculosis
- Clostridium difficile and Clostridium perfringens research
- Biosimilars and Bioanalytical Methods
- Hidradenitis Suppurativa and Treatments
- Diverticular Disease and Complications
- IL-33, ST2, and ILC Pathways
- Celiac Disease Research and Management
- Colorectal Cancer Treatments and Studies
- Immunodeficiency and Autoimmune Disorders
- Helicobacter pylori-related gastroenterology studies
- Anorectal Disease Treatments and Outcomes
- COVID-19 Clinical Research Studies
- Gut microbiota and health
- Cancer Immunotherapy and Biomarkers
- Long-Term Effects of COVID-19
- Gastric Cancer Management and Outcomes
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
Moscow Clinical Scientific Center
2016-2025
Scientific Research Institute of Healthcare Organization and Medical Management
2022-2025
The Alfred Hospital
2016
National Medical and Surgical Center named after N.I. Pirogov
2012
This article reports on the sixth scientific workshop of European Crohn's and Colitis Organisation [ECCO] pathogenesis extraintestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. paper has been drafted by 15 ECCO members 6 external experts [in rheumatology, dermatology, ophthalmology, immunology] from 10 countries USA. Within workshop, contributors formed subgroups to address specific areas. Following a comprehensive literature search, supporting text was finalized under...
Objectives The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate prevalence symptoms and post-COVID-19 disorders gut–brain interaction after hospitalisation for SARS-CoV-2 infection. Design GI-COVID-19 is a prospective, multicentre, controlled study. Patients with without diagnosis were evaluated hospital admission 1, 6 12 months post hospitalisation. Gastrointestinal symptoms, anxiety depression assessed using validated...
Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and compare anti-tumour necrosis factor [anti-TNF] therapy vedolizumab [VDZ] ustekinumab [UST] real-world setting. A retrospective multicentre study CD-adults curative ICR on was undertaken. ePOR defined as Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD 6. Multivariable logistic regression...
.
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the postoperative complications tofacitinib exposure before colectomy in comparison biologics. METHODS: A multicenter, retrospective, observational study was conducted patients UC who underwent total for medically refractory disease, exposed or a biologic surgery. Primary outcome occurrence any complication within 30 (early) and 90 (late) days after...
INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated their occurrence, variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients COVID-19 diagnosis were recruited hospital admission asked for after month, using validated Symptom Rating Scale...
Abstract Background Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) Crohn’s disease (CD) are limited. Methods We conducted a multicenter, retrospective study to assess clinical, biochemical, endoscopic outcomes JAKis bio-experienced UC CD patients. Corticosteroid-free clinical remission (CSFCR) was defined as (CR; CDAI<150 CD, partial Mayo score ≤2 with rectal bleeding subscore 0 UC) not receiving local systemic steroids...
Abstract Background Crohn’s disease (CD) complicated with intra-abdominal abscess often requires surgical intervention. Image guided percutaneous drainage (PD) can help to avoid interventions, however there is limited evidence on the optimal management after PD. Our study aimed analyze long-term outcomes of CD Methods In this multicenter, multinational retrospective trial penetrating patients simplex were enrolled and followed. Baseline was defined as day first detection abdominal abscess,...
Abstract Background JAK inhibitors (JAKi) can induce and maintain remission in inflammatory bowel disease (IBD). Around 5% of IBD patients develop primary sclerosing cholangitis (PSC). Given the potential involvement JAK/STAT signaling PSC pathogenesis, JAKi may have a role modulating IBD-related PSC. We aim to explore course IBD-PSC on for IBD. Methods Following call-for-cases via ECCO CONFER (Round 10), we retrospectively collected baseline outcome data both IBD, before after treatment,...
Abstract Background In patients with inflammatory bowel diseases (IBD), there was a more frequent development of thromboembolic complications, which is due to an increased concentration procoagulants and proinflammatory cytokines. Aim determine the D-dimer interleukin-6 (IL-6) in total ulcerative colitis (UC) during period exacerbation remission disease establish link between them. Methods The study included 38 severe 40 remission. [N=0.0-0.50 mcg/ml] IL-6 [N=0.0-12.7 pg/ml] were determined...
ABSTRACT Background The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has highlighted the potential exacerbation of gastrointestinal symptoms in patients with disorders gut‐brain interaction (DGBIs). However, distinct symptom trajectories and psychological burden post‐COVID‐19 DGBIs compared pre‐existing irritable bowel (IBS)/functional dyspepsia (FD) non‐DGBI controls remain poorly understood. Objectives To examine long‐term progression comorbidities DGBI, IBS/FD...
Background. The incidence of venous thromboembolic complications (VTEC) in patients with inflammatory bowel diseases is approximately 3 times higher than the general population and leads to a 2-fold increase risk mortality. VTEC highest during patient's hospital stay. Aim. To compare overall inpatients ulcerative colitis (UC) without primary prevention. Materials methods. In 2020, anticoagulant therapy was used for UC case acute thrombosis, 2022, thromboprophylaxis moderate high based on...
The National Registry of Patients with Inflammatory Bowel Disease (IBD) in the Russian Federation was established to study epidemiological and clinical characteristics patients evaluate actual practice medical surgical treatment. AIM : analyze data IBD including demographic characteristics, status patients, frequency use various classes drugs response treatment, survival rates advanced therapy reasons for their cancellation. METHODS from May 2017 August 2021, depersonalized 3827 adult...
Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could an option acute severe (ASUC). We aimed investigate efficacy and safety moderate-to-severe ASUC. This retrospective, international study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 July 31, 2022. Indications were categorized as ASUC chronic activity (CA). Baseline demographic clinical data...
Сombination of two or more biological immunosuppressive drugs in order to achieve a synergistic effect patients with refractory inflammatory bowel disease (IBD) has been the spotlight for many years. Combination therapy may include various medications, most often and immunosuppressants. Despite fact that IBD traditionally focused on block tumor necrosis factor-alpha, development new act different targets, such as vedolizumab, ustekinumab, tofacitinib ozanimod, made it possible use combined...
The purpose of this study was to the effectiveness ustekinumab (UST) depending on dosage regimen (90 mg subcutaneously once every 8 or 12 weeks) in patients with Crohn's disease (CD) who have unfavorable prognosis factors. Material and methods. To assess drug, we included 38 CD had factors, were randomized into two groups received drug a 90 subcutaneous weeks (1-st group, n = 20) (2-nd 18). gender age patient analyzed, including at time diagnosis, severity prevalence CD; presence intestinal...
Aim. To compare the effectiveness of effect combination therapy (local and systemic administration) with bone marrow mesenchymal stromal cells (MSC), anticlitokine infliximab (IFX), antibiotic (AB)/immunosuppressive (IS) on frequency healing simple perianal fistulas in Crohn's disease. Materials methods. In our study, 1-st group patients aged 19 to 58 years (Me-29) (n = 12) received MSCs culture systemically according scheme locally. The 2-nd CD 10) from 20 68 old (Me-36) anticytokine (IFX)...
Psoriasis and inflammatory bowel disease (IBD) are multifactorial chronic immuno-inflammatory potentially disabling disorders with similar genetic factors immunological pathways, in particular, polymorphisms of IL-23R, which determines the signal IL-12/23-mediated pathway immunopathogenesis. The emergence genetically engineered biological agents has changed prognosis for both psoriasis IBD. intersection therapeutic spectrum IBD is a very important point when choosing management strategy...
To compare fecal calprotectin (FC) concentration with laboratory and diagnostic methods in patients inflammatory bowel diseases (IBD).The level of FC was measured 110 established IBD. Crohn (CD) diagnosed 50 patients, ileocolitis - 38 terminal ileitis 12 individuals. Ulcerative colitis (UC) 60 total 35, left-side 21 4 have proctitis. Laboratory data include measurement FC, leukocytes, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), occult blood. All underwent colonoileoscopy...
AIM: to demonstrate the first Russian experience with use of tofaciminib (TOFA) for treatment moderate and severe UC in real clinical practice. PATIENTS AND METHODS: eighty-five patients (aged 41.38±14.69 years, average disease duration 9.55±5.27 mild – 3.5%, 41.2%, 52.9%, acute 2.6%), resistant corticosteroid therapy (36.5%) biological agents (61.2%), were prescribed TOFA at an induction dose 10 mg 2 times a day, followed by decrease maintenance (5 day). Early response, endoscopic...
To evaluate the effectiveness of MSCs therapy in patients with CD receiving azathioprine (AZA).The study included 34 inflammatory (luminal) form CD. The 1st group (n=15) received an- ti-inflammatory using culture combination AZA. 2nd (n=19) without severity attack was assessed points accordance Crohn's disease activity index (CDAI). Immunoglobulins (IgA, IgG, IgM), interleukins (IL) 1β, 4, 10, tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), transforming growth factor-1β (TGF-1β),...
The article is devoted to the current data regarding pathogenesis, classification and frequency of extraintestinal manifestations (EIMs) in inflammatory bowel diseases. We discuss two distinct theories EIMs pathogenesis. First, arise from an extension antigen-specific immune responses intestine non-intestinal sites. Second, are independent events initiated or perpetuated by presence IBD shared genetic environmental risk factors host. These mechanisms not mutually exclusive may contribute...
To define the frequency of adverse events and loss response in patients with ulcerative colitis (UC) Crohn’s disease (CD), treated original medicine infliximab (IFX) “Remicaide” its biosimilars.